Addex Therapeutics Ltd ADR (NASDAQ:ADXN) does about 4.26K shares in volume on a normal day but saw 16707530 shares change hands in the recent trading day. The company now has a market cap of 9.50M USD. Its current market price is $11.58, marking an increase of 51.17% compared to the previous close of $7.66. The 52 week high reached by this stock is $27.90 whilst the lowest price level in 52 weeks is $5.00.
Addex Therapeutics Ltd ADR (ADXN) has a 20-day trading average at $7.95 and the current price is -58.49% off the 52-week high compared with 131.60% distance from its 52-week low. The 50-day simple moving average of the closing price is $8.13 and its 200-day simple moving average is $9.41. If we look at the stock’s price movements over the week, volatility stands at 11.47%, which decreases to 7.16% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 78.73 to suggest the stock is overbought.
The consensus objective for the share price is $25.76, suggesting that the stock has a potential upside of 55.05% over the period.
#####
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 31, 2024 when H.C. Wainwright upgraded the stock to “Buy” and issued a price target of $30.
The current price level is 49.04%, 43.39%, and 23.40% away from its SMA20, SMA50, and SMA200 respectively, with the ADXN price moving below the 50-day SMA on current market day. Addex Therapeutics Ltd ADR (ADXN) stock is up 49.81% over the week and 44.75% over the past month. Its price is 91.40% year-to-date and 8.83% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.01 and -0.06 for whole year. Expected sales for next quarter are $240k, which analysts say will come at $990k for the current fiscal year and next year at $950k. In addition, estimates put the company’s current quarterly revenue at an average of $260k.
To reach the target analysts have set, the stock logically needs to grow 55.05 percent from here.
Outstanding shares total 0.82M with insiders holding 0.00% of the shares and institutional holders owning 3.60% of the company’s common stock. The company has a return on equity of -683.70%. The beta has a value of 1.78. Price to sales ratio is 6.13.
#####
